1863065-92-2

AB-CHMINACA is an indazole-based synthetic cannabinoid (CB) that is structurally related to AB-FUBINACA (Item Nos. ISO60211 | ISO00134 | 14039), a high affinity ligand of the CB₁ receptor (K_i = 0.9 nM). MAB-CHMINACA is structurally similar to AB-CHMINACA by bearing an identical cyclohexyl group; however, the isobutyl moiety is substituted with a tert-butyl group. It is a potent agonist of the CB₁ receptor with a reported K_i value of 0.289 nM. This product is intended for forensic and research applications.

N-[1-(Aminocarbonyl)-2,2-dimethylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide is an impurity of MAB-CHMINACA (A105960) and 5-fluoro-ADB-PINACA, an indazole-based synthetic cannabinoid that is structurally related to AB-FUBINACA, a high affinity ligand of the central CB1 receptor. it is also used in the studies on the identification and quantitation of 5-fluoro-ADB-PINACA and MAB-CHMINACA indazole-based cannabinoids in dubious herbal products. Synthetic cannabinoids.

[1] CARLIER J, DIAO X, SEMPIO C, et al. Identification of New Synthetic Cannabinoid ADB-CHMINACA (MAB-CHMINACA) Metabolites in Human Hepatocytes[J]. The AAPS Journal, 2017, 71 2 1: 0. DOI: 10.1208/s12248-016-0037-5
[2] KOUTARO HASEGAWA. Postmortem distribution of MAB-CHMINACA in body fluids and solid tissues of a human cadaver.[J]. Forensic Toxicology, 2015, 33 2: 380-387. DOI: 10.1007/s11419-015-0272-y
[3] PIOTR ADAMOWICZ  Joanna G. Acute intoxication of four individuals following use of the synthetic cannabinoid MAB-CHMINACA.[J]. Clinical toxicology (Philadelphia, Pa.), 2016: 650-654. DOI: 10.1080/15563650.2016.1190016